An observational study focusing on the changes of the upper eyelid sulcus after switching from FP receptor agonist to omidenepag isoproryl ophthalmic solution

An observational study focusing on the changes of the upper eyelid sulcus after switching from FP receptor agonist to EP2 receptor agonist - An observational study focusing on the changes the upper eyelid sulcus after switching to EP2 receptor agonist

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036705

Enrollment

Registered

2019-05-10

Start date

2019-05-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma, ocular hypertension

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) a patient with glaucoma or ocular hypertension 2) a patient treats FP receptor agonist for glaucoma or ocular hypertension 3) a patient who has a desire to change their eyedrops because of impaired quality of life due to the deepening of the upper eyelid sulcus after topical use of FP receptor agonist. And that is the case where it seems to be appropriate to switch from FP receptor agonist to omidenepag isopropyl ophthalmic solution 0.002% by the research group 4) an outpatient

Exclusion criteria

Exclusion criteria: 1) a patient with aphakic or pseudophakic eyes 2) a patient with hypersensitivity to Omidenepag isopropyl ophthalmic solution 0.002%

Design outcomes

Primary

Measure	Time frame
Changes of findings and subjective symptom and quality of life about the upper eyelid sulcus	—

Countries

Japan

Contacts

Public ContactRei Sakata

Yotsuya Shirato Eye Clinic Ophthalmology

reisakata-tky@umin.ac.jp03-3355-4281

Outcome results